How Covid Antibody Infusion Therapy Can Help You

From the beginning of the coronavirus pandemic, the lives lost due to the lack of any temporary yet effective solution were devastating. As patients who tested positive would deteriorate in hospitals until they would eventually succumb to the inevitable.

In response, the Food and Drug Administration (FDA) came out with a temporary solution to a widespread problem in covid antibody infusion, better known as monoclonal antibody infusion treatment. This treatment was mainly introduced for the high at-risk demographic to prevent their symptoms from worsening.

Do get yourself checked out if you qualify for the Covid antibody infusion therapy in Metairie in your next appointment at the doctors’ office.

What are monoclonal antibodies?

Humans have the ability to fight any infection or foreign invader by using antibodies generated within the human body. With sudden introduction and exposure of a virus as deadly as covid-19, the human body was not used to defending the body against this virus. That’s when monoclonal antibodies made in a laboratory come into the scene. These antibodies are created to target a specific virus; in this case, it happens to be covid-19.

This treatment was introduced to reduce the existing symptoms so that the rate of hospitalization would drop.

The people who would be considered as at-risk for severe illness would include:

People aged 65 years and above.
People 55 years and above have either heart disease, respiratory illness, or high blood pressure.
Children 12 years and above have weak immune systems, diabetes, kidney ailments, or are obese.
Adolescents aged 12-17 years with cerebral palsy, chronic respiratory problems, sickle cell disease, heart disease, need a feeding tube or life support, or who are obese.

Based on your condition and severity of symptoms, therapy will be advised.

The covid antibody is only administered to patients tested positive for the virus via an IV or a shot. The antibodies entering the bloodstream will help fight the virus and gradually cause the population of the virus or viral load to dwindle, leading to severe symptoms getting mild. The efficacy of this treatment is high when administered as early as possible.

Here are the eligibility criteria for the therapy:

A person at a high risk of exposure to the virus.
A person not fully vaccinated
Patients with specific medical conditions that do not insure them from kidney dialysis, organ transplant, chemotherapy, and radiation.

Overall prevention is better than cure; hence following social distancing and maintaining hygiene is essential to defeating the virus.